|
| Register for our Free Newsletters |
|
 |
|
|
|
|
|
|
|
|
| Other Carouselweb publications |
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
Horiba ABX becomes Horiba Medical
|
|
Horiba Medical
: 23 February, 2009 (Company News) |
|
|
Horiba ABX, the specialists in the design and manufacture of automated in vitro diagnostics systems for haematology and clinical chemistry applications for over 25 years, has changed its name to Horiba Medical. |
|
|
The new name aims to give Horiba Medical a strong unified identity within the parent Horiba Group which the company joined 12 years ago. The Horiba Group is a global leader in systems for analysing and measuring gases, liquids and solids.
From a simple European start-up company, Horiba Medical has now grown to become one of the world’s leading haematological analysis specialists manufacturing 25 percent of all haematology instruments sold worldwide. Furthermore, over 27,000 laboratories in more than 110 countries are equipped by Horiba Medical due to the quality and versatility of its analysers and associated reagents.
The Horiba Group is listed on the Tokyo and Osaka Stock Exchanges and has 5,000 employees present in 43 subsidiaries worldwide. Horiba Medical will now become further established as a key part of its world leading parent company which comprises five different segments of activity: Medical, Scientific, Process and Environment, Semiconductors and Automotive Testing Systems.
Having ready access to such a diverse technological Group brings significant advantages to Horiba Medical, particularly with regard to product enhancements and new product developments. Horiba Medical’s R and D benefits from all the technologies patented by its parent Horiba Group and from synergies between the Group’s 13 research centres worldwide. Consequently, the company has introduced a number of firsts into the field of in vitro diagnostics, this includes leucocyte counting using flow cytometry and cytochemistry in the smallest automated haematology system on the market, the ABX Pentra 60C+.
Horiba Medical invests more than 10 percent of its turnover in R and D to ensure that it continues to design systems capable of performing increasingly complex analyses, whilst simplifying interpretation of results, which is particularly important in a Point of Care (POC) environment for example.
“Our specific aim is to ensure smooth and efficient blood analysis wherever it is required and the Company has already successfully developed an array of automated analysers to meet all needs,” said Cleve Wright, general manager, Horiba Medical UK. “We look forward to working even more closely with our sister companies within the Horiba Group to continue to meet and exceed our customers’ expectations”.
Horiba Medical’s products range from compact Point-of-Care (POC) analysers to high throughput systems, all designed, developed and distributed worldwide from its European headquarters in Montpellier, France.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
